WFDC2 and supranuclear palsy, progressive, 1: High levels of He4 that significantly correlate with IL-6 and PSP have been detected in COVID-19 patients; for this reason He4 could be used as an innovative biomarker for monitoring the clinical evolution of the disease and for the pharmacological management of these patients.